Nagoya, Pediatrics
A Material Transfer Agreement (MTA) has been established between the Faculty of Medicine at Chulalongkorn University and Nagoya University, Japan, for the production of anti-CD19 chimeric antigen receptor T-cells using the PiggyBac Transposon method, which does not utilize viruses. This research is currently in Phase I clinical trials and has successfully treated five patients with B-cell lymphoma, with the goal of expanding the treatment to other hospitals, including Chulalongkorn Hospital. Additionally, an MTA has been established for the development of anti-BCMA chimeric antigen receptor T-cells using the PiggyBac Transposon method, in collaboration with Chulalongkorn University’s Faculty of Medicine (shared 50%-50%), for future clinical studies.
Qualification
- MD, PhD
Title and Affiliation
- Professor, Graduate School of Medicine Program in Integrated Medicine Medicine in Growth and Aging
Email: [email protected]
Link: https://profs.provost.nagoya-u.ac.jp/html/100003023_en.html
Qualification
- MD, PhD
Title and Affiliation
- Nagoya University Hospital Designated lecturer
Email: [email protected]
Link: https://profs.provost.nagoya-u.ac.jp/html/100008108_en.html
Qualification
- MD, PhD
Title and Affiliation
- Nagoya University Hospital Children's Cancer Center Lecturer of hospital
Email: [email protected]